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Scapuloperoneal (SP) syndrome encompasses heterogeneous neuromuscular disorders characterized by weakness in the shoulder-girdle
and peroneal muscles. In a large Italian-American pedigree with dominant SP myopathy (SPM) previously linked to chromosome 12q,
we have mapped the disease to Xq26, and, in all of the affected individuals, we identiﬁed a missense change (c.365G/C) in the FHL1
gene encoding four-and-a-half-LIM protein 1 (FHL1). The mutation substitutes a serine for a conserved trypophan at amino acid 122 in
the second LIM domain of the protein. Western blot analyses of muscle extracts revealed FHL1 loss that paralleled disease severity. FHL1
and an isoform, FHL1C, are highly expressed in skeletal muscle and may contribute to stability of sarcomeres and sarcolemma, myoﬁ-
brillary assembly, and transcriptional regulation. This is the ﬁrst report, to our knowledge, of X-linked dominant SP myopathy and the
ﬁrst human mutation in FHL1.Scapuloperoneal syndrome (SPS) was initially described
more than 120 years ago by Jules Broussard as ‘‘une forme
he´re´ditaire d’atrophie musculaire progressive’’ beginning
in the lower legs and affecting the shoulder region earlier
and more severely than distal arm;1 however, the etiology
of this condition remains unclear. Descriptions of neuro-
genic SP (MIM 181400) with distal limb sensory loss (Davi-
denkow syndrome) or without sensory involvement
(Kaeser syndrome) as well as SP myopathy (SPM [MIM
181430]) suggest that at least three pathogenically distinct
forms exist.2–5 Molecular genetic studies have conﬁrmed
the existence of more than one cause of SP syndrome. In
1996, we linked an apparently autosomal-dominant SPM
in a large Italian-American family (family C) to chromo-
some 12q6 whereas an autosomal-dominant neurogenic
SP in New England kindred of French-Canadian origin
(MIM 181405) was mapped to a second distinct locus on
chromosome 12q24.7 In the original family reported by
Kaeser, a pathogenic missense mutation (R350P) of the
desmin gene (Des [MIM 125660]) was identiﬁed,4,8 and
in two of 17 patients with scapuloperoneal myopathy,
a missense mutation (R1845W) in the MYH7 gene encod-
ing myosin heavy chain 7 (MIM 160760) was observed.9
In family C, 14 of 44members were deﬁnitely affected by
SPM and two other deceased individuals were probably af-
fected based on clinical history.6 The diagnosis of SPS was
based on clinical features including footdrop as an ‘‘invari-
able early sign,’’ proximal arm weakness always preceding
hand weakness, and scapular winging on examination of
all patients. Elevated serum creatine kinase (CK) levels in
all patients, normal nerve conduction studies with electro-
myographicmyogenic changes, andmuscle biopsies in four208 The American Journal of Human Genetics 82, 208–213, Januarypatients revealing typical myopathic changes indicated
thatmyopathywas the cause ofweakness. Detailed analysis
of two muscle biopsy samples revealed desmin-positive
cytoplasmic bodies indicative of a myoﬁbrillary myopathy.
The prior linkage study mapped the disease to chromo-
some 12q between markers 12S88 (94.49 cM) and 12S306
(105.18) based on a maximum 2-point LOD score of 2.95
(marker D12S82 at recombinant fraction [q] ¼ 0) and
peak multipoint LOD score of 3.0. However, 10 individuals
who were ‘‘not affected’’ shared the chromosome 12q hap-
lotype with the affected individuals suggesting incomplete
penetrance, double recombination in these nonaffected
individuals, or false-positive linkage. Therefore, we per-
formed a new genome-wide scan with microsatellite
markers to identify the chromosomal locus of the disease.
Sex chromosome markers were included because X-linked
dominant inheritance could not be excluded by male-
to-male transmission.
In this study, we re-evaluated 27 adult members of fam-
ily C (Figure 1). Fourteen individuals (8 women and 6men)
were considered affected because they had weakness of
shoulder-girdle and peroneal muscles (MRC grade % 4/5),
scapular winging, and functional impairment. Affected
individuals appear in ﬁve generations. Clinical features,
electrophysiology, morphology, and immunohistochemis-
try of the family have been described.6 We included DNA
samples from the 12 affected individuals analyzed previ-
ously6 plus two additional deﬁnitely affected individuals
previously considered not affected. Two affected individ-
uals (III-32 and IV-6) had died since the prior report. Tissue
samples from the family were collected under Columbia
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Figure 1. Pedigree of SPM Family C
Dark symbols indicate affected individuals. Genotypes are listed below each tested individual (two clinically unaffected are not shown as
they requested). Haplotypes shared among the affected individuals are boxed. Individuals are numbered according to a prior publication.6We performed molecular genetic linkage studies with
leukocyte DNA from 27 family members (14 affected and
13 unaffected individuals). Three unaffected female indi-
viduals allowed us to analyze their DNA but refused publi-
cation of their genetic information; therefore, their hap-
lotypes are not included in the pedigree (Figure 1). 411
ﬂuorescently labeled microsatellite markers were initially
tested (Prevention Genetics, Marshﬁeld, WI). To conﬁrm
the results andnarrowdownthe candidate region,we tested
additional ﬂuorescently labeled microsatellite markers in
the ABI Prism Linkage Mapping Set-MD10 (Applied Biosys-
tems, Foster City, CA). We performed two-point LOD score
analysis with the MLINK option of FASTLINK 5.23 (X-
linked dominant inheritance under the 90% females and
100% male penetrances models; we have used a disease
allele frequency of 0.00 corresponding to 1 in 1000).
We screened three candidate genes for mutations:
MBNL3 (MIM 300413), ZNF75 (MIM 314997), and FHL1
(MIM 300163). To sequence FHL1, we designed 11 primer
pairs ﬂanking the exons, the promoter region, and the 50
and 30 untranslated region. Sequencing was performed
with BigDye 3.1 with an ABI 3100 Genetic AnalyzerThe Am(Applied Biosystems). Screening of 181 healthy individuals
for the G-to-C transition at nucleotide 365 of FHL1 was
performed by restriction fragment length polymorphism
analysis with BsmBI restriction endonuclease digestion of
PCR-ampliﬁed DNA fragments.
Western blot studies were performed with rabbit poly-
clonal antibody anti-FHL1 (AVIVA Systems Biology) at
a dilution of 1:1000 and with mouse monoclonal anti-vin-
culin antibody (Sigma) at a dilution of 1:5000. After wash-
ing, the membranes were incubated with the correspond-
ing anti-rabbit or anti-mouse IgG secondary antibodies
(Dako) at a dilution of 1:1000 for 45 min at room temper-
ature. The membranes were developed with the chemilu-
minescence ECL system (Pharmacia) followed by exposure
of the membranes to autoradiographic ﬁlms. Quantitation
of immunoreactive bands was performed by densitometric
analysis with the NIH Scion Image software package (ver-
sion 1.61).
To generate amodel ofW122Smutant FHL1, we used the
coordinates of PDB entry 1X63 and replaced tryptophan
122 with a serine residue via a common rotamer with the
program COOT. The molecular surface was generated witherican Journal of Human Genetics 82, 208–213, January 2008 209
the program GRASP, and ﬁgures were generated with the
program PYMOL.
Only three microsatellite markers produced LOD scores
R 1.0: TPO (chromosome 2p25), D12S1294 (12q15), and
ATCT003 (Xq26) (see Table S1 available online). We dis-
proved the prior linkage to chromosome 12q because
one affected individual (III-27), who was ‘‘not affected’’
in the prior study, did not share the haplotype with her
affected relatives. We also excluded linkage to the desmin
gene locus at chromosome 2q35.
We tested additional microsatellite markers at chro-
mosome Xq26. Recombinations detected with markers
GATA16B12P and DXS2390 restricted the SPM locus to
a 19 megabase interval with a maximum two-point LOD
score of 3.66 at q ¼ 0 with marker ATCT003 (Table 1). Al-
though the critical region was large, we identiﬁed three
candidate genes, which encode proteins highly expressed
in muscle and are involved in muscle sarcomeric organiza-
tion or muscle differentiation: MBNL3, ZNF75, and FHL1.
Direct DNA sequencing of MBNL3 and ZNF75 did not
reveal any potential mutations; however, in FHL1, we
identiﬁed a G-to-C transition at nucleotide 365 in exon
3 (c.365G/C) that changes a tryptophan in position
122 to serine (W122S). The skeletal muscle LIM protein
1, FHL1 or SLIM1, is a member of the four-and-a-
half-LIM (FHL) domain protein family.10–12 LIM is an acro-
nym of the three transcription factors Lin-11, Isl-1, and
Mec-3 in which the cysteine-rich double zinc ﬁnger motif
(CX2CX17-19HS2C)X2(CX2CX16-20CX2(H/D/C) was origi-
nally identiﬁed.13 The W122S mutation alters a conserved
residue in the second LIM domain of the protein (Figure 2).
The mutation was hemizygous in all the affected males
and heterozygous in all affected females. Affected men
had earlier age at onset (26.15 4.7 years, mean5 standard
deviation; n ¼ 8) than women (34.4 5 11.9 years; n ¼ 8)
(p ¼ 0.04, t test). In addition, men were more severely af-
fected than women: 7 of 8 men became wheelchair bound
earlier (age 35.9 5 4.0 years) and only one was walking
with a cane at age 63, whereas only 4 of 8 women became
wheelchair bound later (age 54.85 19) and four were am-
bulating at ages 33–74. Two unaffected females (III-21 and
an individual who requested to be anonymous) carry the
mutation, but because both are <58 years old, the oldest
age at onset among deﬁnitely affected individuals, they
are presumed to be presymptomatic. We did not detect







0 0.01 0.05 0.1 0.2 0.3 0.4
GATA165B12 77.15 6.05 3.81 1.45 0.43 0.39 0.58 0.42
DXS8009 82.07 0.54 0.55 0.58 0.59 0.54 0.41 0.23
ATCT003 82.07 3.66 3.65 3.57 3.38 2.82 2.06 1.10
DXS1047 82.07 2.86 2.87 2.85 2.74 2.33 1.72 0.94
DXS1062 82.24 1.52 1.50 1.40 1.28 1.01 0.71 0.38
DXS2390 95.00 4.90 0.43 1.67 2.02 2.00 1.58 0.89210 The American Journal of Human Genetics 82, 208–213, Januarythe mutation in 181 unrelated and unaffected Italian-
American individuals, 54 females and 127 males (235 X
chromosomes); 40 individuals were of Italian origin. We
also excluded FHL1 mutations in 10 unrelated patients
with myoﬁbrillar myopathy and 5 unrelated probands
with the clinical diagnosis of SP syndrome.
We performed western blot analyses to quantitate levels
of FHL1 and vinculin (a sarcolemmal protein) with quadri-
ceps muscle from two affected men (III-24 and IV-18), two
affected women (III-14 and III-32), and two controls (Fig-
ure 3). Levels of vinculin were comparable in all muscle
samples, but amounts of FHL1 normalized to vinculin
were inversely related to the duration of symptoms at the
time of biopsy. Individual IV-18 had weakness for 12 years
and his FHL1/vinculin ratio, 0.74, was comparable to both
controls (0.75 and 1.0). In contrast, in relatives affected for
longer periods, the ratios were reduced to 0.3 in III-14
(weak for 26 years), 0.4 in III-32 (weak for 39 years), and
0.0001 in IV-18 (weak for 25 years). It is noteworthy that
the severely affected man had signiﬁcantly lower FHL1
than his female relatives, who had less weakness with
similar durations of symptoms.
To conﬁrm that loss of protein was disease speciﬁc, west-
ern blot analyses of FHL1 and vinculin were performed
with extracts of muscles from two patients with cyto-
plasmic body myopathy, two patients with myoﬁbrillar
myopathy not caused by mutations in FHL1, and two con-
trols. The ratios of FHL1/vinculin were comparable in all
muscle samples (controls, 1 and 1.15; cytoplasmic body
myopathies, 1.17 and 0.9; and myoﬁbrillar myopathies,
0.7 and 0.73).
Figure 2. Evolutionary Conservation of Tryptophan-122 in
FHL1
Tryptophan at amino acid 122 (arrow) in human FHL1 is highly
conserved across species.
Figure 3. FHL1 Protein Expression in SPM Patients
Western blot analysis of FHL1 and vinculin in skeletal muscle of
four patients (P1, III-24; P2, III-14; P3, III-32; and P4, IV-18)
with the W122S FHL1 mutation and two controls.2008
Trytophan at amino acid 122 of FHL1 is conserved in all
four LIM domains of FHL1 and in the consensus LIMmotif
(Figure 4A). To assess the potential structural effects of the
mutation on FHL1, we used a model derived from an NMR
structural determination of a segment containing residues
91–159 of FHL1 (PDB entry 1x63) (Figures 4B and 4C). In
this structural model, there are apparent van der Waals
contacts between wild-type W122 with neighboring
F127, T120, and K107. The interactions with T120 and
K102 would be lost when W122 is replaced by a smaller
Figure 4. Structural Analysis of the
FHL1 W122S Mutation
(A) Sequence alignment of the 4 LIM do-
mains in FHL1 demonstrates 13 conserved
amino acids (highlighted in red) including
8 residues (indicated by asterisks) that co-
ordinate the two zinc ions. The secondary
structure indicated on the first line is de-
rived from an NMR model containing the
second LIM domain (PDB, 1X63). Amino
acid numbers refer to the second LIM do-
main. An arrow indicates the position of
the disease-associated W122S mutation.
(B) The structure of LIM domain 2 of FHL1
is shown as a cartoon diagram. Wild-type
residue W122 (in cyan) is replaced by ser-
ine (in magenta) in affected individuals.
A molecular surface calculated for the mu-
tant protein with GRASP26 and colored to
demonstrate the predicted electrostatic
potential (blue is positive charge and red
is negative). Substitution of the normal
Trp residue by a smaller Ser side chain is
likely to change the surface of the protein.
Side chains of the residues that coordinate
the zinc ions (shown as spheres) are shown
in stick representation, as well as the
nearby conserved F127.
(C) Apparent van der Waals contacts be-
tween wild-type W122 with neighboring
F127, T120, and K107 are shown as over-
lapping clouds of small spheres in an image
generated with PYMOL (DeLano Scientific
LLC).
serine, and therefore, the mutation
may affect folding and stability of
this LIM domain, conformation of
the adjacent second zinc ﬁnger bind-
ing domain, or both. Alternatively,
because W122 is adjacent to the pre-
dicted protein-binding surface of the
FHL1, interactions with protein part-
ners could be affected by the muta-
tion (Figures 4B and 4C). Based on
our western blot analysis indicating
loss of FHL1 in parallel with disease
severity, we hypothesize that the
mutation may cause instability or selective destruction of
misfolded protein.14
The LIM motif mediates protein-protein interactions
with transcription factors, cell-signaling molecules, and
cytoskeleton-associated proteins.15 The FHL family in-
cludes FHL1, FHL2, FHL3, FHL4, and ACT in humans.
Whereas expression of FHL4 and ACT is restricted to testis,
FHL1, FHL2, and FHL3 are mainly expressed in muscle.
FHL2 and FHL3 also contribute to themechanical stabiliza-
tion of muscle cells.16The American Journal of Human Genetics 82, 208–213, January 2008 211
FHL1 is the least characterized of the FHL proteins; it con-
tains an N-terminal single zinc ﬁnger followed by four LIM
domains, which are separated by eight intervening amino
acids. FHL1 is highly expressed in adult human skeletalmus-
cle,moderately inheart, andweakly in placenta, ovary, pros-
tate, testis, small intestine, colon, and spleen.10–12 In cul-
tured C2C12 skeletal muscle cell lines, levels of FHL1 and
FHL3 transcripts appear to be coordinated with expression
ofmyogenic factors includingMyoD,MRF4, andmyogenin,
suggesting that FHL1 and FHL3 participate inmyogenesis.17
FHL1 may contribute to muscle cytoarchitecture by in-
teracting with myosin-binding protein C (MyBP-C) and
has been localized to the I-band and M-line of sarcomeres as
well as to sarcolemma, where it colocalizes with MyBP-C.18
RNAi knockdown of FHL1 in C2C12 cells impaired myosin
thick ﬁlament formation and reduced MyBP-C incorpora-
tion into sarcomeres, indicating that FHL1 is required for
sarcomere assembly.18 In addition, FHL1 may have a role
in a5b1-integrin-dependent myocyte elongation, adhe-
sion, spreading, and migration.19,20
Two additional transcripts of the FHL1 gene have been
described: FHL1B (SLIMMER) and FHL1C (KyoT2).21–23
FHL1B is expressed mainly in brain whereas FHL1C is pri-
marily in skeletal muscle. All three transcripts share exons
1–3, which encode the N-terminal single zinc ﬁnger and
two LIM domains. Isoforms FHL1B and 1C lack exon 4 (en-
coding two LIM domains of FHL1) and contain a C-termi-
nal putative binding domain for J-recombination signal
protein (RBP-J),21–23 a transcription factor required for de-
velopment and negatively regulated by KyoT2 inmice;24,25
therefore, human FHL1C may modulate muscle transcrip-
tion by repressing RBP-J transcription.
Based on the putative functions of FHL1 and FLH1C pro-
teins in skeletal muscle, we hypothesize that the W122S
mutation causes focal myoﬁbrillary disarray though possi-
ble disruption of stability of sarcomeres and sarcolemma,
myoﬁbrillary assembly, transcriptional regulation, or
a combination of these functions. The identiﬁcation of
FHL1, MHC7, and Desmutations in patients with scapulo-
peroneal myopathy suggests that myoﬁbrillary disarray
may be a common feature of SP syndrome.8,9 Further stud-
ies are needed to elucidate the role of FHL1 in skeletal
muscle and the pathomechanism of FHL1 in this novel
X-linked dominant myopathy.
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